Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Non-Current Deffered Revenue: 2023-2024

Historic Non-Current Deffered Revenue for BridgeBio Pharma (BBIO) over the last 2 years, with Dec 2024 value amounting to $17.1 million.

  • BridgeBio Pharma's Non-Current Deffered Revenue fell 29.51% to $13.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.1 million, marking a year-over-year decrease of 29.51%. This contributed to the annual value of $17.1 million for FY2024, which is 358.68% up from last year.
  • BridgeBio Pharma's Non-Current Deffered Revenue amounted to $17.1 million in FY2024, which was up 358.68% from $3.7 million recorded in FY2023.
  • Over the past 5 years, BridgeBio Pharma's Non-Current Deffered Revenue peaked at $17.1 million during FY2024, and registered a low of $3.7 million during FY2023.
  • Over the past 2 years, BridgeBio Pharma's median Non-Current Deffered Revenue value was $10.4 million (recorded in 2023), while the average stood at $10.4 million.
  • Data for BridgeBio Pharma's Non-Current Deffered Revenue shows a peak YoY soared of 358.68% (in 2024) over the last 5 years.
  • Yearly analysis of 2 years shows BridgeBio Pharma's Non-Current Deffered Revenue stood at $3.7 million in 2023, then spiked by 358.68% to $17.1 million in 2024.